Language impairment in alzheimer's disease and benefits of acetylcholinesterase inhibitors

Steven H. Ferris, Martin Farlow

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function, a number of language-specific scales have been developed to assess language deficits throughout progression of the disease and to evaluate the effects of pharmacotherapy on language function. Trials of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer's disease, have generally focused on overall cognitive effects. However, in the current report, we review data indicating specific beneficial effects of acetylcholinesterase inhibitors on language abilities in patients with Alzheimer's disease, with a particular focus on outcomes among patients in the moderate and severe disease stages, during which communication is at risk and preservation is particularly important.

Original languageEnglish
Pages (from-to)1007-1014
Number of pages8
JournalClinical Interventions in Aging
Volume8
DOIs
StatePublished - 2013

Fingerprint

Cholinesterase Inhibitors
Alzheimer Disease
Language
Aptitude
Semantics
Cognition
Disease Progression
Communication
Drug Therapy

Keywords

  • Alzheimer's disease
  • Clinical trials
  • Cognition
  • Communication
  • Donepezil
  • Language

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Language impairment in alzheimer's disease and benefits of acetylcholinesterase inhibitors. / Ferris, Steven H.; Farlow, Martin.

In: Clinical Interventions in Aging, Vol. 8, 2013, p. 1007-1014.

Research output: Contribution to journalArticle

@article{41514af3fac64800aac51748ac99be02,
title = "Language impairment in alzheimer's disease and benefits of acetylcholinesterase inhibitors",
abstract = "Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function, a number of language-specific scales have been developed to assess language deficits throughout progression of the disease and to evaluate the effects of pharmacotherapy on language function. Trials of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer's disease, have generally focused on overall cognitive effects. However, in the current report, we review data indicating specific beneficial effects of acetylcholinesterase inhibitors on language abilities in patients with Alzheimer's disease, with a particular focus on outcomes among patients in the moderate and severe disease stages, during which communication is at risk and preservation is particularly important.",
keywords = "Alzheimer's disease, Clinical trials, Cognition, Communication, Donepezil, Language",
author = "Ferris, {Steven H.} and Martin Farlow",
year = "2013",
doi = "10.2147/CIA.S39959",
language = "English",
volume = "8",
pages = "1007--1014",
journal = "Clinical Interventions in Aging",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Language impairment in alzheimer's disease and benefits of acetylcholinesterase inhibitors

AU - Ferris, Steven H.

AU - Farlow, Martin

PY - 2013

Y1 - 2013

N2 - Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function, a number of language-specific scales have been developed to assess language deficits throughout progression of the disease and to evaluate the effects of pharmacotherapy on language function. Trials of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer's disease, have generally focused on overall cognitive effects. However, in the current report, we review data indicating specific beneficial effects of acetylcholinesterase inhibitors on language abilities in patients with Alzheimer's disease, with a particular focus on outcomes among patients in the moderate and severe disease stages, during which communication is at risk and preservation is particularly important.

AB - Alzheimer's disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer's disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function, a number of language-specific scales have been developed to assess language deficits throughout progression of the disease and to evaluate the effects of pharmacotherapy on language function. Trials of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer's disease, have generally focused on overall cognitive effects. However, in the current report, we review data indicating specific beneficial effects of acetylcholinesterase inhibitors on language abilities in patients with Alzheimer's disease, with a particular focus on outcomes among patients in the moderate and severe disease stages, during which communication is at risk and preservation is particularly important.

KW - Alzheimer's disease

KW - Clinical trials

KW - Cognition

KW - Communication

KW - Donepezil

KW - Language

UR - http://www.scopus.com/inward/record.url?scp=84881062258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881062258&partnerID=8YFLogxK

U2 - 10.2147/CIA.S39959

DO - 10.2147/CIA.S39959

M3 - Article

C2 - 23946647

AN - SCOPUS:84881062258

VL - 8

SP - 1007

EP - 1014

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

SN - 1176-9092

ER -